{
  "original_data": {
    "question": "A 58-year-old male with a history of obesity and hypertension presents to his primary care physician for a follow-up visit. He reports that he feels well and has no complaints. He currently takes hydrochlorothiazide. His temperature is 98.6°F (37°C), blood pressure is 135/80 mmHg, pulse is 86/min, and respirations are 17/min. His BMI is 31 kg/m2. Results of a lipid panel are: Total cholesterol is 280 mg/dl, triglycerides are 110 mg/dl, HDL cholesterol is 40 mg/dl, and LDL cholesterol is 195 mg/dl. Her physician considers starting her on atorvastatin. Which of the following will most likely decrease after initiating this medication?",
    "options": {
      "A": "Mevalonate",
      "B": "Acetoacetyl-CoA",
      "C": "Diacyglycerol",
      "D": "High-density lipoprotein"
    }
  },
  "model_response": "The mevalonate pathway is the biosynthetic pathway from 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to cholesterol and various other isoprenoids. This pathway is inhibited by the cholesterol-lowering drug lovastatin, which is a competitive inhibitor of the enzyme HMG-CoA reductase. Atorvastatin is also an HMG-CoA reductase inhibitor. The end product of the mevalonate pathway, cholesterol, is an important component of cell membranes and precursor of bile acids, steroid hormones, and vitamin D. The pathway also produces isoprenoids, which are important components of a number of other cellular compounds, including the sterol ring in the structure of the vitamin ergocalciferol (vitamin D2). The pathway begins with acetoacetyl-CoA, which is produced in the mitochondria from acetyl-CoA. Acetoacetyl-CoA then moves to the cytoplasm, where it is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). HMG-CoA is then reduced to mevalonate by HMG-CoA reductase. The next step in the pathway is the condensation of mevalonate with a phosphate to form 5-phosphomevalonate. This reaction is catalyzed by mevalonate kinase. The product of this reaction is then isomerized to form the activated isoprenoid intermediate diacyglycerol (DAG). DAG is then used to activate protein kinase C (PKC), which phosphorylates a variety of cellular proteins, leading to changes in cell metabolism, cell growth, and cell death. Lovastatin and pravastatin reduce cholesterol synthesis by competitively inhibiting the enzyme HMG-CoA reductase. Lovastatin is metabolized by the CYP3A isoform of cytochrome P450.\n\n###Answer: OPTION A IS CORRECT.</s><s>",
  "question_entities": [
    {
      "text": "male",
      "type": "T032",
      "umls_id": "C0086582",
      "score": 0.9951750040054321,
      "semantic_types": [
        "T032"
      ],
      "definition": "A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both."
    },
    {
      "text": "history",
      "type": "T090",
      "umls_id": "C0019664",
      "score": 0.994277834892273,
      "semantic_types": [
        "T090"
      ],
      "definition": "Record and study of past events."
    },
    {
      "text": "obesity",
      "type": "T047",
      "umls_id": "C0028754",
      "score": 0.9890912771224976,
      "semantic_types": [
        "T047"
      ],
      "definition": "A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY)."
    },
    {
      "text": "hypertension",
      "type": "T047",
      "umls_id": "C0020538",
      "score": 0.9838637709617615,
      "semantic_types": [
        "T047"
      ],
      "definition": "Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more."
    },
    {
      "text": "primary care physician",
      "type": "T097",
      "umls_id": "C0033131",
      "score": 0.9911936521530151,
      "semantic_types": [
        "T097"
      ],
      "definition": "Providers of initial care for patients. These PHYSICIANS refer patients when appropriate for secondary or specialist care."
    },
    {
      "text": "follow-up visit",
      "type": "T058",
      "umls_id": "C0589121",
      "score": 0.9691847562789917,
      "semantic_types": [
        "T058"
      ],
      "definition": null
    },
    {
      "text": "reports",
      "type": "T170",
      "umls_id": "C0684224",
      "score": 0.9694634079933167,
      "semantic_types": [
        "T170"
      ],
      "definition": "Detailed account or statement or formal record of the proceedings of a meeting or session. May also document status or progress of an activity or research project."
    },
    {
      "text": "feels",
      "type": "T041",
      "umls_id": "C1527305",
      "score": 0.9925816655158997,
      "semantic_types": [
        "T041"
      ],
      "definition": "Emotional sensations."
    },
    {
      "text": "hydrochlorothiazide",
      "type": "T109",
      "umls_id": "C0020261",
      "score": 0.9853209853172302,
      "semantic_types": [
        "T109",
        "T121"
      ],
      "definition": "A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism."
    },
    {
      "text": "temperature",
      "type": "T032",
      "umls_id": "C0005903",
      "score": 0.9769303798675537,
      "semantic_types": [
        "T032"
      ],
      "definition": "The measure of the level of heat of a human or animal."
    },
    {
      "text": "blood pressure",
      "type": "T040",
      "umls_id": "C0005823",
      "score": 0.9879373908042908,
      "semantic_types": [
        "T040"
      ],
      "definition": "PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS."
    },
    {
      "text": "mmHg",
      "type": "T081",
      "umls_id": "C0439475",
      "score": 0.989119827747345,
      "semantic_types": [
        "T081"
      ],
      "definition": "A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC."
    },
    {
      "text": "pulse",
      "type": "T058",
      "umls_id": "C0034107",
      "score": 0.9736508727073669,
      "semantic_types": [
        "T058"
      ],
      "definition": "The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts."
    },
    {
      "text": "respirations",
      "type": "T039",
      "umls_id": "C0035203",
      "score": 0.9742469787597656,
      "semantic_types": [
        "T039"
      ],
      "definition": "The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration (= OXYGEN CONSUMPTION) or cell respiration (= CELL RESPIRATION)."
    },
    {
      "text": "BMI",
      "type": "T060",
      "umls_id": "C0005893",
      "score": 0.9942916631698608,
      "semantic_types": [
        "T060"
      ],
      "definition": null
    },
    {
      "text": "lipid panel",
      "type": "T059",
      "umls_id": "C0200382",
      "score": 0.9889910817146301,
      "semantic_types": [
        "T059"
      ],
      "definition": null
    },
    {
      "text": "Total cholesterol",
      "type": "T034",
      "umls_id": "C0543421",
      "score": 0.9837814569473267,
      "semantic_types": [
        "T034"
      ],
      "definition": null
    },
    {
      "text": "triglycerides",
      "type": "T109",
      "umls_id": "C0041004",
      "score": 0.9742359519004822,
      "semantic_types": [
        "T109",
        "T123"
      ],
      "definition": "An ester formed from GLYCEROL and three fatty acid groups."
    },
    {
      "text": "HDL cholesterol",
      "type": "T109",
      "umls_id": "C0023822",
      "score": 0.9464987516403198,
      "semantic_types": [
        "T109",
        "T123"
      ],
      "definition": "Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol."
    },
    {
      "text": "LDL cholesterol",
      "type": "T109",
      "umls_id": "C0023824",
      "score": 0.9515059590339661,
      "semantic_types": [
        "T109",
        "T123"
      ],
      "definition": "Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol."
    },
    {
      "text": "physician",
      "type": "T097",
      "umls_id": "C0031831",
      "score": 0.9965500235557556,
      "semantic_types": [
        "T097"
      ],
      "definition": "Individuals licensed to practice medicine."
    },
    {
      "text": "considers",
      "type": "T033",
      "umls_id": "C0518609",
      "score": 0.7161739468574524,
      "semantic_types": [
        "T033"
      ],
      "definition": "Careful thought or deliberation."
    },
    {
      "text": "atorvastatin",
      "type": "T109",
      "umls_id": "C0286651",
      "score": 0.9552493691444397,
      "semantic_types": [
        "T109",
        "T121"
      ],
      "definition": "A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)"
    },
    {
      "text": "decrease",
      "type": "T033",
      "umls_id": "C0392756",
      "score": 0.9790282249450684,
      "semantic_types": [
        "T033"
      ],
      "definition": "Made less in size or amount or degree."
    },
    {
      "text": "medication",
      "type": "T121",
      "umls_id": "C0013227",
      "score": 0.9858695864677429,
      "semantic_types": [
        "T121"
      ],
      "definition": "Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form."
    },
    {
      "text": "58-year-old",
      "type": "AGE_VALUE",
      "umls_id": null,
      "score": null,
      "semantic_types": null,
      "definition": null
    }
  ]
}